Anti-suicidal effects of IV ketamine in a real-world setting
O'Brien B, Lee J, Kim S, Nandra G, Pannu P, Tamman A, Amarneh D, Swann A, Murphy N, Averill L, Jha M, Mathew S. Anti-suicidal effects of IV ketamine in a real-world setting. Psychiatry Research 2023, 331: 115604. PMID: 38064911, DOI: 10.1016/j.psychres.2023.115604.Peer-Reviewed Original ResearchConceptsKetamine treatmentIntravenous ketamine treatmentProportion of patientsAnti-suicidal effectsGroup of patientsTwo-week courseKetamine effectsSymptoms of suicidalityPatientsReal-world settingClinical samplesRapid improvementTrajectory groupsBaselinePossible effectivenessTreatmentScoresKetamineSymptomsGradual improvementSuicidalityDemographic variablesPresent studyHigher scoresCurrent studyRegistered clinical trials investigating ketamine and esketamine for treatment-resistant depression: A systematic review
Brendle M, Ragnhildstveit A, Slayton M, Smart L, Cunningham S, Zimmerman M, Seli P, Gaffrey M, Averill L, Robison R. Registered clinical trials investigating ketamine and esketamine for treatment-resistant depression: A systematic review. Journal Of Psychedelic Studies 2023, 6: 176-187. DOI: 10.1556/2054.2022.00234.Peer-Reviewed Original ResearchTreatment-resistant depressionMontgomery-Asberg Depression Rating ScaleDepression Rating ScaleLate-phase trialsTrial eligibilityPatient characteristicsDrug regimensClinical outcomesResults databaseRegistered trialsClinical trialsTreatment responseEsketaminePharmacological approachesPRISMA guidelinesCombination treatmentMost trialsClinical practiceElectronic registryKetamineSystematic reviewFinal reviewTherapeutic useQualitative synthesisStudy design